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http://dx.doi.org/10.1016/j.jacl.2017.01OBJECTIVE: This study was performed to evaluate the effects of vitamin D and omega-3 fatty acids
co-supplementation on glucose metabolism and lipid concentrations in gestational diabetes (GDM)
patients.
METHODS: This randomized double-blind placebo-controlled clinical trial was done among 140
GDM patients. Participants were randomly divided into 4 groups to receive: (1) 1000 mg omega-3 fatty
acids containing 360 mg eicosapentaenoic acid and 240 mg docosahexaenoic acid (DHA) twice a
day 1 vitamin D placebo (n 5 35); (2) 50,000 IU vitamin D every 2 weeks 1 omega-3 fatty acids
placebo (n 5 35); (3) 50,000 IU vitamin D every 2 weeks 1 1000 mg omega-3 fatty acids twice a
day (n 5 35), and (4) vitamin D placebo 1 omega-3 fatty acids placebo (n 5 35) for 6 weeks.
RESULTS: After 6 weeks of intervention, patients who received combined vitamin D and omega-3
fatty acids supplements compared with vitamin D, omega-3 fatty acids, and placebo had significantly
decreased fasting plasma glucose (27.3 6 7.8, 26.9 6 6.6, 24.0 6 2.5, and 11.0 6 11.4 mg/dL,
respectively, P , .001), serum insulin levels (21.9 6 1.9, 21.3 6 6.3, 20.4 6 6.3,
and 12.6 6 6.5 mIU/mL, respectively, P 5 .005), homeostatic model of assessment for insulin resis-
tance (20.7 6 0.6, 20.5 6 1.4, 20.2 6 1.5, and 10.6 6 1.5, respectively, P , .001) and increased
quantitative insulin sensitivity check index (10.01 6 0.01, 10.008 6 0.02, 10.002 6 0.02, and
20.005 6 0.02, respectively, P 5 .001). In addition, changes in serum triglycerides
(28.2 6 41.0, 17.6 6 31.5, 13.6 6 29.9, and 120.1 6 29.6 mg/dL, respectively, P 5 .006) andt of Biochemistry and Nutrition,
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460 Journal of Clinical Lipidology, Vol 11, No 2, April 2017very low–density lipoprotein cholesterol (21.6 6 8.2, 11.5 6 6.3, 10.8 6 6.0, and 14.0 6 5.9 mg/
dL, respectively, P 5 .006) in the vitamin D plus omega-3 fatty acids group were significantly different
from the changes in these indicators in the vitamin D, omega-3 fatty acids, and placebo groups.
CONCLUSION: Overall, vitamin D and omega-3 fatty acids co-supplementation for 6 weeks among
GDM patients had beneficial effects on fasting plasma glucose, serum insulin levels, homeostatic
model of assessment for insulin resistance, quantitative insulin sensitivity check index, serum triglyc-
erides, and very low–density lipoprotein cholesterol levels.
 2017 National Lipid Association. All rights reserved.Introduction
Gestational diabetes (GDM) is defined as any carbohy-
drate intolerance and impaired insulin metabolism with the
onset or first recognition during pregnancy.1 GDM affects
1% to 14% of pregnancies depending on the diagnostic
criteria, gestational age, and characteristics of the study
population.2 GDM is associated with a marked effect on
the future health of both mother and offspring including
pre-eclampsia,3 shoulder dystocia, higher rates of cesarean
section,4 macrosomia, neonatal hypoglycemia, and respira-
tory distress syndrome.5 In addition, hyperinsulinemia and
hyperglycemia during pregnancy have the potential to be
detrimental to growth and metabolism in the offspring.6
Dyslipidemia is associated with type II diabetes mellitus,7
endothelial dysfunction, atherosclerosis, and intrauterine
growth retardation.8
Prior studies have suggested that circulating levels of
vitamin D9 and omega-3 fatty acids10 were low in GDM sub-
jects than those healthy pregnant women. In addition, data
on the effect of vitamin D or omega-3 fatty acids supplemen-
tation alone on metabolic profiles are conflicting. Nowadays,
there is a growing interest to use vitamin D and omega-3
fatty acids during pregnancy. The basis of this interest is
because of both vitamin D deficiency during pregnancy11
and the results of epidemiologic observations exhibiting
the significant inverse association between vitamin D or
omega-3 fatty acids and pregnancy complications.12,13
Furthermore, few studies have reported the beneficial effects
of vitamin D or omega-3 fatty acids supplementation alone
among GDM women. We have previously shown that
vitamin D treatment at dosage of 50,000 IU every 3 weeks
for 6 weeks in women with GDM improved glycemia, total
cholesterol, and LDL cholesterol concentrations but did not
influence other lipid profiles.14 Improved insulin resistance
was also observed after the intake of 1000 mg omega-3 fatty
acids per day for 6 weeks in GDM subjects, but unchanged
plasma glucose, insulin sensitivity, and lipid profiles.15 In
another study by Baidal et al.16 was seen that combined
high-dose omega-3 fatty acids and high-dose vitamin D3
therapy improved beta-cell function in patients with new
onset type I diabetes mellitus.
There are speculations that vitamin D and omega-3 fatty
acids may improve metabolic status because of their shared
functions and each nutrient-specific role that complements
the other nutrient’s functions.17,18 This trial was, therefore,conducted to investigate the effects of vitamin D and omega-
3 fatty acids co-supplementation on parameters of glucose
homeostasis and lipid concentrations in GDM women.Methods
Trial design
The present study was a 6-week prospective randomized
double-blind placebo controlled clinical trial.
Participants
This study was done among 140 GDM subjects aged 18-
40 years without prior diabetes that have been diagnosed
with GDM by ‘‘one-step’’ 2-h 75-g oral glucose tolerance
test (OGTT) at 24-28 weeks’ gestation referred to Kosar
Clinic in Arak, Iran from March 2016 to July 2016. We
diagnosed GDM based on the American Diabetes Associ-
ation guidelines19: those whose plasma glucose met 1 of the
following criteria were considered as having GDM: fasting
plasma glucose (FPG) $ 92 mg/dL, 1-hour OGTT
$ 180 mg/dL, and 2-hour OGTT $ 153 mg/dL.19 Exclu-
sion criteria were taking vitamin D and/or omega-3 fatty
acids supplements, taking insulin, placenta abruption, pre-
eclampsia, eclampsia, hypothyroidism and hyperthyroid-
ism, smokers, those with kidney or liver diseases.
Ethics statements
This research was conducted according to the principles
of the Declaration of Helsinki, and the study protocol was
approved by the ethics committee of Arak University of
Medical Sciences (reference number IR.ARAK-
MU.REC.1394.373). The study protocol was carefully
explained to all subjects before obtaining informed consent
form. This trial was registered in the Iranian Web site
(www.irct.ir) for registration of clinical trials (http://www.
irct.ir: IRCT201605135623N78).
Study design
Patients were initially randomized to ‘‘intervention vs
Placebo,’’ and then divided into the 4 groups to intake
omega-3 fatty acids (n 5 35), vitamin D (n 5 35), vitamin
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cebo (n 5 35) for 6 weeks. At the onset of the study, pa-
tients were requested not to change their routine physical
activity or usual dietary intakes throughout the study and
not to consume any supplements other than the one pro-
vided to them by the investigators as well as not to take
any medications that might affect findings during the
6-week intervention. Dietary macro- and micro-nutrients
intakes were assessed using the 3-day food records
(comprising 2 working days and 1 weekend) at the onset,
weeks 3, 5, and end of the intervention. All participants’
physical activity records were completed at weeks 0, 3,
and 6 of the intervention. Modified Nutritionist-4 software
program (First Databank, San Bruno, CA) was used to es-
timate the energy and nutrient intakes. In the present study,
physical activity was described as metabolic equivalents
(METs) in hours per day. To determine the METs for
each patient, we multiplied the times (in hour per day) re-
ported for each physical activity by its related METs coef-
ficient by standard tables.20
Intervention
In the intervention groups, participants were received (1)
1000 mg omega-3 fatty acids containing 360 mg eicosa-
pentaenoic acid (EPA) and 240 mg docosahexaenoic acid
(DHA) twice a day 1 vitamin D placebo (n 5 35); (2)
50,000 IU vitamin D every 2 weeks 1 omega-3 fatty acids
placebo (n 5 35); and (3) 50,000 IU vitamin D every
2 weeks 1 1000 mg omega-3 fatty acids twice a day
(n 5 35) for 6 weeks. The appearance of the placebo
capsule was indistinguishable in color, shape, size, and
packaging, smell, and taste from vitamin D and omega-3
fatty acids capsules. Vitamin D and omega-3 fatty acids
capsules were produced by Zahravi Pharmaceutical Com-
pany, Tabriz, Iran, that approved by Food and Drug
Administration.
Treatment adherence
Every 2 weeks, individuals were taken enough supple-
ments and placebos to last 3 days after their next scheduled
visit and were instructed to return all unused supplements at
each visit. The remaining supplements were counted and
subtracted from the number provided to determine the
number taken. To increase the compliance, all persons were
receiving short messages on their cell phones to take the
supplements every day.
Assessment of anthropometric measurements
Weight and height (Seca, Hamburg, Germany) were
taken by a nutritionist before and after treatment in a
fasting status without shoes and a minimal clothing state by
a trained midwife. Body mass index (BMI) was calculated
using the height and weight measurements (weight in
kg/[height in meters]2).Assessment of outcomes
The primary outcome measurements were markers of
insulin metabolism in the present study. The secondary
outcome measurements were lipid concentrations.
Biochemical assessment
Blood sample was drawn at weeks 0 and 6 after at least
12-h fasting. All blood samples were centrifuged at 3000g
for 10 minutes, and serum were separated into the clean
tube aliquots and were stored at 280C until analysis at
the Arak University of Medical Sciences Reference Labo-
ratory. To determine FPG, serum triglycerides, very low–
density lipoprotein (VLDL) cholesterol, total cholesterol,
low-density lipoprotein and high-density lipoprotein
(HDL)-cholesterol concentrations, we used enzymatic kits
(Pars Azmun, Tehran, Iran). All inter-assay and intra-
assay coefficient variances (CVs) for FPG and lipid
concentrations were lower than 5%. Serum 25-
hydroxyvitamin D concentrations were quantified using a
commercial enzyme-linked immunosorbent assay kit
(IDS, Boldon, UK) with the intra-assay and inter-assay
CVs 5.1% and 7.1%, respectively. Circulating levels of
serum insulin were determined by use of the enzyme-
linked immunosorbent assay kit (Monobind, CA) with the
intra-assay and inter-assay CVs 3.0% and 4.7%, respec-
tively. The homeostatic model of assessment for insulin
resistance (HOMA-IR), homeostatic model assessment for
B-cell function (HOMA-B), and the quantitative insulin
sensitivity check index (QUICKI) were determined accord-
ing to suggested formulas.21
Sample size
To calculate sample size, we used the standard formula
suggested for parallel clinical trials by considering type I
error (a) of 0.05 and type II error (b) of 0.20
(power 5 80%). Based on a previous study,14 we used
1.41 as standard deviation and 1.03 as the difference in
mean (d) of HOMA-IR as key variable. Based on this, we
needed 30 persons in each group. Assuming 5 dropouts in
each group, the final sample size was determined to be 35
persons per group.
Randomization
Randomization assignment as blinding was done using
computer-generated random numbers by a trained staff at
the gynecology clinic.
Statistical methods
The Kolmogorov–Smirnov test was used to examine the
normal distribution of variables. The analyses were done
based on intention-to-treat approach. One-way analysis of
variance (ANOVA) was used to detect differences in
462 Journal of Clinical Lipidology, Vol 11, No 2, April 2017general characteristics, dietary intakes, and metabolic pro-
files at the study baseline between the 4 groups. To
determine the effects of vitamin D plus omega-3 fatty
acids supplementation on markers of insulin metabolism
and lipid profiles, we used repeated measures ANOVA.
Changes in metabolic profiles across 4 groups were
compared using repeated measure ANOVA. To assess if
the magnitude of the change depended on the baseline
values, we adjusted all analyses for the baseline values,
maternal age, and baseline BMI to avoid the potential bias
that might have resulted. P values ,.05 were considered
statistically significant. All statistical analyses were done
using the Statistical Package for Social Science version
17 (SPSS Inc, Chicago, IL).
Results
Among individuals in the omega-3 fatty acids group, 3
patients (withdrawal because of personal reasons [n 5 3])
were excluded. The exclusions in the placebo group were
3 persons (withdrawal because of personal reasons
[n 5 3]). Finally, 140 subjects (vitamin D [n 5 35],
omega-3 fatty acid [n 5 35], vitamin D plus omega-3 fatty
acids [n 5 35], and placebo [n 5 35]) completed the trial
(Figure 1). However, as the analysis was done based on
intention-to-treat approach, all 140 subjects (35 in eachLost to follow-up due to 
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Figure 1 Summary of patient flow diagram. 1Individuals received 50
acids twice a day; 2individuals received 1000 mg omega-3 fatty acid
acid) twice a day plus placebo for vitamin D every 2 weeks; 3individ
omega-3 fatty acids twice a day.group) were included in the final analysis. No side effects
were reported after supplementation of vitamin D and
omega-3 fatty acids in GDM women throughout the study
as well as vitamin D and omega-3 fatty acids were tolerated
in particular in terms gastrointestinal tolerance.
Mean age, height, baseline, and end-of-intervention
weight and BMI of study participants were not statistically
different between the 4 groups (Table 1).
Based on the 3-day dietary records obtained throughout
the intervention, no statistically significant difference was
seen between the 4 groups in terms of dietary intakes of
macronutrients and micronutrients (data not shown).
No significant differences were observed between the 4
groups in terms of baseline values of markers of insulin
metabolism and lipid profiles (Table 2).
Co-supplementation with vitamin D and omega-3 fatty
acids resulted in a significant increase in serum 25-
hydroxyvitamin D concentrations (121.5 6 3.4,
119.2 6 3.9, 10.9 6 2.7, and 20.1 6 1.7 mg/dL,
respectively, P , .001) compared with vitamin D, omega-
3 fatty acids, and placebo (Table 3). After 6 weeks of inter-
vention, patients who received combined vitamin D and
omega-3 fatty acids supplements compared with vitamin
D, omega-3 fatty acids, and placebo had significantly
decreased FPG (27.3 6 7.8, 26.9 6 6.6, 24.0 6 2.5,
and 11.0 6 11.4 mg/dL, respectively, P , .001), serumAnalyzed (n=35)
Lost to follow-up due to 
withdraw (n=3) 
d (n=140)
ibility (n=160)
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Not living in Arak (n=10) 
Not meeting inclusion criteria (n=10) 
Allocated to omega-32
(n=35)
Allocated to vitamin D plus 
omega-3 3 (n=35)
Lost to follow-up (n=0)
Analyzed (n=35)
,000 IU vitamin D every 2 weeks plus placebo for omega-3 fatty
s (360 mg eicosapentaenoic acid and 240 mg docosahexaenoic
uals received 50,000 IU vitamin D every 2 weeks plus 1000 mg
Table 1 General characteristics of study participants*
General characteristics
Placebo
(n 5 35)
Vitamin D†
(n 5 35)
Omega-3‡
(n 5 35)
Vitamin D 1 omega-3x
(n 5 35) P{
Age (y) 30.7 6 4.1 31.5 6 7.0 30.7 6 3.5 31.2 6 4.3 .87
Height (cm) 161.5 6 5.0 162.3 6 5.8 161.6 6 3.5 161.4 6 4.2 .86
Weight at study baseline (kg) 75.9 6 7.1 78.4 6 15.2 75.0 6 5.8 77.3 6 9.9 .52
Weight at end-of-trial (kg) 77.9 6 7.8 80.6 6 14.9 77.1 6 5.7 79.5 6 9.9 .48
Weight change (kg) 2.0 6 0.7 2.2 6 1.1 2.1 6 0.6 2.2 6 0.6 .74
BMI at study baseline (kg/m2) 29.2 6 3.4 29.7 6 5.1 28.8 6 2.4 29.7 6 3.9 .67
BMI at end-of-trial (kg/m2) 29.9 6 3.4 30.5 6 5.0 29.6 6 2.4 30.5 6 3.9 .64
BMI change (kg/m2) 0.7 6 0.3 0.8 6 0.4 0.8 6 0.2 0.8 6 0.2 .76
BMI, body mass index.
*Data are means6 standard deviations.
†Receiving 50,000 IU vitamin D every 2 weeks plus placebo for omega-3 fatty acids twice a day.
‡Receiving 1000 mg omega-3 fatty acids (360 mg eicosapentaenoic acid and 240 mg docosahexaenoic acid) twice a day plus placebo for vitamin D
every 2 weeks.
xReceiving 50,000 IU vitamin D every 2 weeks plus 1000 mg omega-3 fatty acids twice a day.
{Obtained from analysis of variance test.
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and 12.6 6 6.5 mIU/mL, respectively, P 5 .005),
HOMA-IR (20.7 6 0.6, 20.5 6 1.4, 20.2 6 1.5,
and 10.6 6 1.5, respectively, P , .001), and increased
QUICKI (10.01 6 0.01, 10.008 6 0.02, 10.002 6
0.02, and 20.005 6 0.02, respectively, P 5 .001). In addi-
tion, changes in serum triglycerides (28.2 6 41.0, 17.6 6
31.5, 13.6 6 29.9, and 120.1 6 29.6 mg/dL, respectively,
P 5 .006) and VLDL-cholesterol (21.6 6 8.2, 11.5 6
6.3, 10.8 6 6.0, and 14.0 6 5.9 mg/dL, respectively,Table 2 The baseline metabolic profiles of study participants*
Metabolic profiles
Placebo
(n 5 35)
Vitamin D†
(n 5 35)
Vitamin D (ng/mL) 16.6 6 2.6 15.2 6 3.8
FPG (mg/dL) 93.6 6 8.9 96.0 6 3.9
Insulin (mIU/mL) 13.2 6 4.7 13.2 6 6.4
HOMA-IR 3.1 6 1.2 3.1 6 1.5
HOMA-B 47.4 6 17.5 46.4 6 24.7
QUICKI 0.32 6 0.02 0.32 6 0.01
Triglycerides (mg/dL) 182.6 6 63.6 172.6 6 72.3
VLDL-cholesterol (mg/dL) 36.5 6 12.7 34.5 6 14.5
Total cholesterol (mg/dL) 208.7 6 43.5 197.1 6 37.3
LDL-cholesterol (mg/dL) 112.0 6 30.1 104.1 6 39.3
HDL-cholesterol (mg/dL) 60.1 6 14.2 58.5 6 7.2
Total-/HDL-cholesterol 3.6 6 0.9 3.4 6 0.8
FPG, fasting plasma glucose; HDL-cholesterol, high-density lipoprotein ch
HOMA-IR, homeostasis model of assessment-insulin resistance; LDL-choleste
sensitivity check index; VLDL-cholesterol, very low–density lipoprotein cholest
*Data are means6 standard deviations.
†Receiving 50,000 IU vitamin D every 2 weeks plus placebo for omega-3 fa
‡Receiving 1000 mg omega-3 fatty acids (360 mg eicosapentaenoic acid an
every 2 weeks.
xReceiving 50,000 IU vitamin D every 2 weeks plus 1000 mg omega-3 fatt
{Obtained from analysis of variance test.P 5 .006) in the vitamin D plus omega-3 fatty acids group
were significantly different from the changes in these indi-
cators in the vitamin D, omega-3 fatty acids, and placebo
groups. Co-supplementation with vitamin D and omega-3
fatty acids had no significant effects on HOMA-B and other
lipid profiles levels.
When the analyses were adjusted for baseline levels,
maternal age, and baseline BMI, no significant changes in
our findings occurred except for HOMA-B (P , .001;
Table 4).Omega-3‡
(n 5 35)
Vitamin D 1 omega-3x
(n 5 35) P{
16.9 6 3.5 15.5 6 3.1 .07
96.5 6 3.9 94.1 6 9.6 .24
12.9 6 4.7 11.9 6 2.5 .62
3.1 6 1.1 2.8 6 0.7 .60
44.7 6 16.4 42.4 6 9.4 .67
0.32 6 0.01 0.32 6 0.01 .90
205.6 6 76.2 201.0 6 92.5 .23
41.1 6 15.2 40.2 6 18.5 .23
217.5 6 48.3 204.3 6 41.7 .25
118.1 6 42.8 107.5 6 47.3 .50
58.2 6 10.2 56.6 6 8.3 .55
3.8 6 1.1 3.7 6 1.0 .34
olesterol; HOMA-B, homeostatic model assessment-Beta cell function;
rol, low-density lipoprotein cholesterol; QUICKI, quantitative insulin
erol.
tty acids twice a day.
d 240 mg docosahexaenoic acid) twice a day plus placebo for vitamin D
y acids twice a day.
Table 3 The effect of vitamin D plus omega-3 supplementations on glucose metabolism and lipid profiles in GDM patients*
Metabolic profiles
End-of-trial Changes from baseline
Placebo
(n 5 35)
Vitamin D†
(n 5 35)
Omega-3‡
(n 5 35)
Vitamin D 1
Omega-3x
(n 5 35) P{
Placebo
(n 5 35)
Vitamin D†
(n 5 35)
Omega-3‡
(n 5 35)
Vitamin D 1
Omega-3x
(n 5 35) P{
Vitamin D (ng/mL) 16.5 6 2.6 34.4 6 6.1 17.8 6 3.7 37.1 6 4.0 ,.001 20.1 6 1.7 19.2 6 3.9k 0.9 6 2.7# 21.5 6 3.4k ,.001
FPG (mg/dL) 94.6 6 10.3 89.1 6 6.8 92.5 6 4.2 86.8 6 6.4 ,.001 1.0 6 11.4 26.9 6 6.6k 24.0 6 2.5k 27.3 6 7.8k ,.001
Insulin (mIU/mL) 15.8 6 7.9 13.2 6 6.4 12.5 6 4.1 11.9 6 2.5 ,.001 2.6 6 6.5 21.3 6 6.3k 20.4 6 6.3 21.9 6 1.9k .005
HOMA-IR 3.7 6 1.9 2.6 6 1.1 2.8 6 0.9 2.1 6 0.5 ,.001 0.6 6 1.6 20.5 6 1.4k 20.2 6 1.5 20.7 6 0.6k ,.001
HOMA-B 56.9 6 31.0 44.9 6 22.5 45.1 6 15.9 38.4 6 10.3 .005 9.5 6 24.4 21.5 6 25.6 0.4 6 24.2 24.0 6 6.1 .05
QUICKI 0.32 6 0.002 0.33 6 0.01 0.32 6 0.01 0.34 6 0.009 ,.001 20.005 6 0.02 0.008 6 0.02k 0.002 6 0.02 0.01 6 0.01k .001
Triglycerides (mg/dL) 202.7 6 68.8 180.2 6 79.8 209.2 6 71.4 192.8 6 85.6 .41 20.1 6 29.6 7.6 6 31.5 3.6 6 29.9 28.2 6 41.0k .006
VLDL-cholesterol (mg/dL) 40.5 6 13.8 36.0 6 16.0 41.9 6 14.3 38.6 6 17.1 .41 4.0 6 5.9 1.5 6 6.3 0.8 6 6.0 21.6 6 8.2k .006
Total cholesterol (mg/dL) 212.0 6 40.3 196.6 6 41.8 218.1 6 50.2 201.7 6 36.1 .14 3.3 6 18.6 20.5 6 23.3 0.6 6 27.0 22.6 6 27.8 .78
LDL-cholesterol (mg/dL) 112.6 6 30.6 101.6 6 39.3 117.2 6 45.9 106.1 6 43.0 .37 0.6 6 14.8 22.5 6 17.7 20.9 6 24.4 21.4 6 23.6 .94
HDL-cholesterol (mg/dL) 58.9 6 12.4 58.9 6 8.5 59.1 6 10.7 60.0 6 9.2 .80 21.2 6 4.9 0.4 6 4.5 0.8 6 4.2 0.4 6 6.3 .30
Total-/HDL-cholesterol 3.7 6 1.0 3.4 6 0.9 3.8 6 1.2 3.6 6 0.9 .34 0.1 6 0.4 20.03 6 0.3 20.01 6 0.7 20.06 6 0.5 .29
FPG, fasting plasma glucose; GDM, gestational diabetes mellitus; HDL-cholesterol, high-density lipoprotein cholesterol; HOMA-B, homeostatic model assessment-Beta cell function; HOMA-IR, homeostasis
model of assessment-insulin resistance; LDL-cholesterol, low-density lipoprotein cholesterol; QUICKI, quantitative insulin sensitivity check index; VLDL-cholesterol, very low–density lipoprotein cholesterol.
*Data are means6 standard deviations.
†Receiving 50,000 IU vitamin D every 2 weeks plus placebo for omega-3 fatty acids twice a day.
‡Receiving 1000 mg omega-3 fatty acids (360 mg eicosapentaenoic acid and 240 mg docosahexaenoic acid) twice a day plus placebo for vitamin D every 2 weeks.
xReceiving 50,000 IU vitamin D every 2 weeks plus 1000 mg omega-3 fatty acids twice a day.
{Obtained from analysis of variance test.
kSignificant difference with the placebo group.
#Significant difference with the vitamin D and vitamin D plus omega-3 fatty acids groups.
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We found that combined vitamin D and omega-3 fatty
acids supplementation for 6 weeks among GDM patients
had the beneficial effects on glycemic control, triglycerides,
and VLDL-cholesterol levels. To the best of our knowl-
edge, this study is the first that reports the effect of vitamin
D and omega-3 fatty acids co-supplementation on glycemic
control and lipid concentrations in GDM patients. It must
be kept in mind that in the present study, observed changes
in glycemic control measures in the combined vitamin D
and omega-3 fatty acids group compared with other groups
were clinically significant. On the other hand, the percent-
age of those who was treated after intervention was also
significantly different between the 4 groups (91.4% for
combined vitamin D and omega-3 fatty acids vs 74.3% for
vitamin D, 71.9% for omega-3 fatty acids, and 59.4% for
placebo groups, P 5 .02). Hyperglycemia and hyperinsuli-
nemia in GDM patients can result in the progression to type
II diabetes mellitus later in life and neonatal complications
including macrosomia and hyperbilirubinemia.22 There-
fore, vitamin D and omega-3 fatty acids co-
supplementation due to their decreasing effects on FPG
and insulin resistance may be useful to decrease maternal
and neonatal complications. However, observed difference
at lipid profiles in our study was statistically significant,
it was not clinically significant. Long-term interventions
and higher dosage of omega-3 fatty acids might result in
greater changes in lipid profiles.Table 4 Adjusted changes in metabolic variables in GDM patients w
acids, and vitamin D supplements or placebo*
Metabolic profiles
Placebo
(n 5 35)
Vitamin D
(n 5 35
Vitamin D (ng/mL) 20.1 6 0.5 19.1 6 0
FPG (mg/dL) 0.2 6 1.1 26.4 6 1
Insulin (mIU/mL) 2.7 6 0.8 21.1 6 0
HOMA-IR 0.7 6 0.2 20.4 6 0
HOMA-B 10.5 6 3.3 20.6 6 3
QUICKI 20.005 6 0.003 0.008 6 0
Triglycerides (mg/dL) 19.5 6 5.5 5.5 6 5
VLDL-cholesterol (mg/dL) 3.9 6 1.1 1.1 6 1
Total cholesterol (mg/dL) 3.8 6 4.0 22.5 6 4
LDL-cholesterol (mg/dL) 0.9 6 3.3 23.5 6 3
HDL-cholesterol (mg/dL) 21.1 6 0.8 0.4 6 0
Total: HDL cholesterol ratio 0.13 6 0.07 20.05 6 0
FPG, fasting plasma glucose; GDM, gestational diabetes mellitus; HOMA-B, h
model of assessment-insulin resistance; HDL-cholesterol, high-density lipopr
QUICKI, quantitative insulin sensitivity check index; VLDL-cholesterol, very low
*All values are means6 standard errors. Values are adjusted for baseline v
†Receiving 50,000 IU vitamin D every 2 weeks plus placebo for omega-3 fa
‡Receiving 1000 mg omega-3 fatty acids (360 mg eicosapentaenoic acid an
every 2 weeks.
xReceiving 50,000 IU vitamin D every 2 weeks plus 1000 mg omega-3 fatt
{Obtained from analysis of covariance test.The present study demonstrated that taking vitamin D
and omega-3 fatty acids supplements among GDM patients
for 6 weeks led to significant reductions in FPG, insulin
concentrations, HOMA-IR, and a significant increase in
QUICKI compared with other groups, but unchanged
HOMA-B. Although few studies have evaluated the favor-
able effects of vitamin D or omega-3 fatty acids supple-
mentation on glucose homeostasis parameters, to the best
of our knowledge, no study has assessed the effects of
vitamin D and omega-3 fatty acids co-supplementation on
glycemic control resistance. We have previously shown
that supplementation with 50,000 IU vitamin D every
3 weeks14 or 1000 mg omega-3 fatty acids per day15 for
6 weeks in pregnant women with GDM had beneficial ef-
fects on parameters of insulin metabolism. In addition, a
single injection of 300,000 IU vitamin D3 at 3 to
10 days after delivery decreased indices of insulin resis-
tance in women with recent pregnancy complicated by
GDM.23 The administration of 2.4 g/d EPA 1 DHA for
8 weeks also decreased serum insulin concentrations and
HOMA-IR among hemodialysis subjects.24 However,
50,000 IU vitamin D supplementation every 2 weeks for
2 months among GDM women improved FPG and
HbA1c, but had no significant effect on markers of insulin
metabolism.25 Moreover, DHA supplementation at the
dosage of 800 mg/d in the second half of pregnancy did
not reduce the risk of GDM.26 The beneficial effects of
vitamin D on glycemic control might be explained by its
effect on calcium and phosphorus metabolism and throughho received vitamin D plus omega-3 fatty acids, omega-3 fatty
†
)
Omega-3‡
(n 5 35)
Vitamin D 1
omega-3x
(n 5 35) P{
.5 1.0 6 0.5 21.5 6 0.5 ,.001
.1 23.0 6 1.1 28.0 6 1.1 ,.001
.8 20.5 6 0.8 22.4 6 0.8 ,.001
.2 20.2 6 0.2 20.8 6 0.2 ,.001
.3 20.2 6 3.3 25.3 6 3.3 .01
.003 0.002 6 0.003 0.01 6 0.003 ,.001
.6 5.5 6 5.6 27.4 6 5.5 .01
.1 1.1 6 1.1 21.5 6 1.1 .01
.0 22.7 6 4.0 23.1 6 4.0 .51
.3 0.2 6 3.3 21.7 6 3.3 .79
.8 0.9 6 0.8 0.1 6 0.8 .38
.08 20.002 6 0.08 20.06 6 0.07 .28
omeostatic model assessment-Beta cell function; HOMA-IR, homeostasis
otein cholesterol; LDL-cholesterol, low-density lipoprotein cholesterol;
–density lipoprotein cholesterol.
alues, age and baseline weight.
tty acids twice a day.
d 240 mg docosahexaenoic acid) twice a day plus placebo for vitamin D
y acids twice a day.
466 Journal of Clinical Lipidology, Vol 11, No 2, April 2017upregulation of the insulin receptor genes27 and increased
transcription of insulin receptor genes.27 Inhibiting proin-
flammatory factors and nuclear factor kappa-light-chain-
enhancer of activated B cells protein expression by
omega-3 fatty acids may result in improvement of markers
of insulin metabolism.28 We hypothesize that combination
therapy with vitamin D and omega-3 fatty acids in patients
with GDM may work better than a single supplementation
alone. Combined vitamin D and omega-3 fatty acids sup-
plementation might also have a strong synergistic effect
on glucose metabolism and lipid profiles. In a study by
Gurol et al.29 was seen that omega-3 fatty acids and
vitamin D had a synergistic effect on glycemia in islet
transplantation. In addition, omega-3 fatty acids supple-
mentation may result in increased levels of vitamin D. In
a study by An et al.30 was observed that 1,25(OH)2D levels
significantly increased in dialysis patients compared with
baseline after 3 months of omega-3 fatty acids administra-
tion without vitamin D. Treatment with omega-3 fatty
acids may also overcome the inverse association of vitamin
D deficiency with inflammation.31 As most patients of our
study had vitamin D deficiency, decreased inflammation
may decrease insulin resistance.
We demonstrated that vitamin D plus omega-3 fatty
acids supplementation in GDM women for 6 weeks
resulted in significant reductions in serum triglycerides
and VLDL-cholesterol concentrations compared with other
groups, but did not influence serum lipid profiles. In a study
by Davis et al.32 was observed that vitamin D and omega-3
fatty acids co-supplementation for 18 months among
asymptomatic adult’s decreased triglycerides, total choles-
terol and LDL-cholesterol, and increased HDL-cholesterol
concentrations. Supplementation with high-dose vitamin
D (50,000 IU/wk) for 4 months in patients with metabolic
syndrome also decreased triglycerides levels, but it did
not had any beneficial effects on other lipid profiles.33 In
addition, a 3-month fish oil supplementation in young
healthy men decreased serum triglycerides, whereas the
proportion of HDL-cholesterol (relative to total cholesterol)
increased significantly.34 Both increased maternal triglycer-
ides and free fatty acids concentrations in GDM women
correlated with fetal growth during pregnancy and with
neonatal anthropometric measures.35 Furthermore, prior
studies have demonstrated that increased maternal lipid
profiles are associated with complications such as macroso-
mia,36 pre-eclampsia,37 and preterm birth.38 Different study
designs, lack of considering baseline levels of dependent
variables along with characteristics of study participants,
different dosages of vitamin D and omega-3 fatty acids sup-
plements as well as duration of the intervention might pro-
vide some reasons for discrepant findings. Vitamin D intake
might improve lipid profiles by increased calcium absorp-
tion39 and improved insulin sensitivity.40 Moreover,
omega-3 fatty acids intake may decrease triglycerides and
VLDL-cholesterol levels through improved postprandial
clearance of chylomicrons41 and decreasing hepatic pro-
duction of VLDL-cholesterol.42Few limitations must be considered in the interpretation
of our findings. The main limitation of our study is the lack
of measurements of fatty acids fractions at study baseline
and at the end-of-trial because of budget limitations.
Further studies are also needed to evaluate the expressed
levels of related variables with signaling pathway of
insulin and lipids to explore the plausible mechanism
and confirm our findings. In addition, this study was a
single-center study, and therefore may not be generalizable
to the overall population of women with GDM. Further
studies are needed to confirm our findings. It must be kept
in mind that in the present study, we used the dose of
2000 mg omega-3 fatty acids based on observed beneficial
effects of omega-3 fatty acids supplementation on insulin
and HOMA levels in a previous study in patients with
polycystic ovary syndrome.43 However, several studies
used higher doses up to 4 grams in polycystic ovary syn-
drome women44 and 2.4 g/d EPA 1 DHA among hemodi-
alysis subjects,24 we agree that future studies are needed
with higher dosage of omega-3 fatty acids in GDM
women.Conclusion
Overall, vitamin D and omega-3 fatty acids
co-supplementation for 6 weeks among GDM patients
had beneficial effects on FPG, serum insulin levels,
HOMA-IR, QUICKI, serum triglycerides, and VLDL-
cholesterol levels, but did not affect HOMA-B and other
lipid profiles.Acknowledgment
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